Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal
cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Background We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and
leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought …

In 2012, there were 447000 new cases of colorectal cancer (CRC) in Europe. CRC is the
second most frequent cancer and represents 13.2% and 12.7% of all cancer cases in men …

Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many
new treatment methods have been developed during recent decades. The Japanese …

Background Treatment with cetuximab, a monoclonal antibody directed against the
epidermal growth factor receptor, improves overall and progression-free survival and …

Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …